Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 2/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2330290 | 0.81 | DGAT1 (0.38) | DGAT1ALDH1A1MAPTPTGS1 | |
| SCHEMBL4939145 | 0.80 | DGAT1 (0.40) | DGAT1ALDH1A1 | |
| SCHEMBL28195825 | 0.80 | DGAT1 (0.40) | DGAT1ALDH1A1 | |
| SCHEMBL9116850 | 0.80 | DGAT1 (0.40) | DGAT1ALDH1A1 | |
| SCHEMBL27708714 | 0.80 | CTSS (0.36) | DGAT1 | |
| SCHEMBL10803405 | 0.80 | DGAT1 (0.34) | DGAT1 | |
| SCHEMBL15375658 | 0.79 | ALDH1A1 (0.35) | DGAT1ALDH1A1MAPTPTGS1NOS1 | |
| SCHEMBL27780857 | 0.78 | LTA4H (0.44) | ALDH1A1 | |
| SCHEMBL3378309 | 0.78 | DGAT1 (0.35) | DGAT1 | |
| SCHEMBL28292144 | 0.77 | CTSK (0.38) | DGAT1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306053-A1 | Highly selective rho-kinase inhibitor | D. WESTERN THERAPEUTICS INSTITUTE, INC. (JP) | 2009-12-10 | — | — | US | disclosed |
| EP-1878732-B1 | HIGHLY SELECTIVE Rho-KINASE INHIBITOR | WESTERN THERAPEUTICS INST INC (JP) | 2009-02-25 | — | — | EP | disclosed |
| EP-1878732-A1 | HIGHLY SELECTIVE Rho-KINASE INHIBITOR | D. Western Therapeutics Institute (JP) | 2008-01-16 | — | — | EP | disclosed |
| WO-2007131286-A1 | NANOSTRUCTURES SUITABLE FOR DELIVERY OF AGENTS | APOLLO LIFE SCIENCES LIMITED (AU) | 2007-11-22 | — | — | WO | disclosed |
| WO-2004076434-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | AIC (BE) | 2004-09-10 | — | — | WO | disclosed |
| WO-2004076433-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | AIC (BE) | 2004-09-10 | — | — | WO | disclosed |
| US-4410688-A | POLYAMIDES FROM DIAMINOCARBOXYLIC ACIDS | ALLIED CORPORATION (US) | 1983-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306053-A1 | Highly selective rho-kinase inhibitor | ROCK1, ROCK2, RHOT2 | DGAT1 2853/4885ALDH1A1 2609/4885MAPT 1271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.